Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast
Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day. The company, ...
Fort Myers-based cancer lab expects strong performance in 2025, with new CEO
NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...
NeoGenomics Maintains Buy Rating Amid Leadership Changes and Strategic Focus Shift
In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of ...